

Anders Nykjaer, et al.  
U.S. Serial No.: 10/539,443; Filed: June 20, 2005  
Amendment in Response to Final Office Action submitted March 23, 2010  
Page 2

**Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-90. (Canceled)

Claim 91. (Previously presented) The method of claim 93, wherein the receptor is exposed to the antibody in an amount of from 1  $\mu\text{g/kg}$  to about 100 mg/kg per day.

Claim 92. (Canceled)

Claim 93. (Currently amended) A method for inhibiting the binding of a ~~pro-neurotrophin~~ pro-NGF to a sortilin ~~receptor of the Vps10p-domain receptor family~~ in an animal, ~~wherein the animal suffers from an injury or dysfunction of the central or peripheral nervous system in need of increased survival of neurons~~, which comprises exposing said receptor to an inhibitor effective amount of an antibody which binds to an extracellular part of such ~~[[a]]~~ receptor, and thereby inhibits the binding of a ~~pro-neurotrophin~~ pro-NGF to said receptor.

Claim 94. (Previously presented) The method of claim 93, wherein the animal is a human being.

Claims 95-96. (Canceled)

Claim 97. (Previously presented) The method of claim 93, wherein the antibody binds to a peptide comprising amino acid residues 612-740 of SEQ ID NO:1.

Anders Nykjaer, et al.

U.S. Serial No.: 10/539,443; Filed: June 20, 2005

Amendment in Response to Final Office Action submitted March 23, 2010

Page 3

Claim 98. (Previously presented) The method of claim 93, wherein the antibody binds to a peptide comprising amino acid residues 24-77 of SEQ ID NO:1.

Claims 99-100. (Canceled)